These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12923828)

  • 21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
    Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT; Isaac MB; Gallo F; Tournoux A
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.
    Okuda A; Suzuki T; Kishi T; Yamanouchi Y; Umeda K; Haitoh H; Hashimoto S; Ozaki N; Iwata N
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):268-73. PubMed ID: 20602727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
    Kato M; Nonen S; Serretti A; Tetsuo S; Takekita Y; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2013 Feb; 33(1):131-2. PubMed ID: 23288236
    [No Abstract]   [Full Text] [Related]  

  • 29. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical use of milnacipran for depression.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Feb; 18(1):34-5. PubMed ID: 12648895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
    Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
    Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and tolerability of paroxetine in the treatment of the depressive phase of bipolar disorders].
    Ambrosio LA; Buccomino D; Filippo A; Morelli A; Musacchio R; Pupo F; Romano FE; Marchese G; Barrese E
    Minerva Psichiatr; 1996 Jun; 37(2):91-7. PubMed ID: 8926862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
    Fukuchi T; Kanemoto K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.